• linkedin
  • Increase Font
  • Sharebar

    2017’s big breakthroughs


    Siliq’s launch

    The launch of Siliq (brodalumab/Valeant Pharmaceuticals) in 2017 was a big step forward for those who suffer from severe psoriasis, says Lawrence J Green, M.D., associate clinical professor of dermatology, George Washington University School of Medicine.

    Dr. Green“Being an IL-17 receptor blocker, Siliq has a different mechanism of action (than other IL-17 antagonists) that theoretically allows it to work in a more thorough way to treat hard to treat psoriatic disease,” says Dr. Green, who has no conflicts of interest on the topic. “From its uniquely rapid onset of action to its high PASI 90 and 100 scores in clinical trials, I feel Siliq is the advancement for 2017.”

    But while Siliq shines for its outcomes in adults with moderate-to-severe plaque psoriasis, dermatologists who prescribe brodalumab may face a rough road, according to a July 2017 article in Dermatology Times.

    NEXT: A better understanding of hyperhidrosis

    Lisette Hilton
    Lisette Hilton, president of Words Come Alive, has written about health care, the science and business of medicine, fitness and wellness ...


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow